Charlottetown, PE – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) is pleased to announce the appointment of Patrick Daoust as Director of Technical Training, effective October 25, 2021.
CASTL provides world-class technical skills development and training in life sciences specializing in biopharmaceutical manufacturing for Canada. It is a first-of-its-kind partnership between academia, industry, and government to address the future skills needs of Canada’s fast-growing bioscience sector. CASTL is the exclusive provider of National Institute for Bioprocessing Research and Training (NIBRT) licensed training programs in Canada. Based in Ireland, NIBRT develops and delivers state-of-the-art training and education programs for the world’s leading biopharmaceutical manufacturing companies and partner academic institutions.
As Director of Technical Training, Patrick will be responsible for leading and directing the various innovative training programs through CASTL’s exclusive partnership with NIBRT. He will also take a leadership role in CASTL’s training facility design, and management, engage with industry on training needs and lead training program implementation. Working with a team of trainers, Patrick will ensure that CASTL offers a best-in-class training experience to both academic and industry partners.
“We are thrilled to have Patrick join the CASTL team, bringing his extensive industry experience and knowledge as our lead on technical training,” said Penny Walsh-McGuire, Executive Director, CASTL. “This is an important step forward as CASTL further develops our national skills and training network for Canada’s biopharmaceutical manufacturing sector.”
A seasoned industry professional, Patrick has 20 years of experience in life sciences process development and manufacturing. He has led multidisciplinary teams in both manufacturing process development and production of clinical material. His technical experience covers Chemistry Manufacturing and Controls (CMC) process development and clinical manufacturing for monoclonal antibodies, fusion proteins and all aspects of antibody drug conjugate development and manufacturing as well as process re-development for Phase 3/Commercial readiness. He has also overseen aseptic drug product fills for multiple clinical lots.
After acquiring expertise in the development of biosimilars, Patrick founded and ran a company dedicated to the development and out-licensing of cell lines and manufacturing processes for various biotherapeutics. He later provided consulting services and then managed various aspects of development and manufacturing for a successful biotech company. Most recently as the Director of Manufacturing at Immune Biosolutions, Patrick led the set-up and successful first production of a clinical lot of a novel antibody treatment for COVID-19. In these roles, Patrick was responsible for developing highly skilled teams by providing complex training to colleagues and employees to ensure success.
Patrick grew up in the Maritimes and completed a BSc in Biotechnology from Sherbrooke University as well as an MSc from the Department of Microbiology and Immunology at University of Montreal.